P 135 asthma and copd

13 - 14

APRIL2015

Holiday Inn Regents Park Hotel, London, UK

Asthma & COPD

@SMIPHARM

www.asthma-copd.co.uk Register online or fax your registration to +44 (0) 870 9090 712 or call +44 (0) 870 9090 711

ACADEMIC & GROUP DISCOUNTS AVAILABLE

CHAIRS FOR 2015:• Sebastian Johnston, Professor of

Respiratory Medicine, National Heart andLung Institute, Imperial College London

• Robert Niven, Senior Lecturer in RespiratoryMedicine, Manchester University

KEY SPEAKERS INCLUDE: • Neil C Thomson, Professor of Respiratory

Medicine, University of Glasgow

• Joseph Arron, Associate Director, Biomarker Discovery, Genentech, Inc.

• Dirk Smith, Scientific Director, Amgen

• Roland Kolbeck, Senior Director, Respiratory,Inflammation & Autoimmunity, MedImmune

• Hector Ortega, Medical Director, RespiratoryR&D, GSK

• Maria Buxton, Consultant RespiratoryPhysiotherapist, London North WestHealthcare NHS Trust

PLUS AN INTERACTIVE HALF-DAY POST-CONFERENCE WORKSHOPWednesday 15th April 2015, Holiday Inn Regents Park Hotel, LondonThe power of functional respiratory imaging to define new endpoints

and drive successful respiratory drug developmentWorkshop Leaders: Dr. Vos Wim, Chief Technology Officer, FLUIDDA,

Prof. Dr. Wilfried De Backer, Director, Professor of Pulmonary Medicine, University Hospital and University of Antwerp8.30am - 12.30pm

BUSINESS BENEFITS FOR 2015:• Explore the future of asthma and COPD treatment

from a range of key perspectives• Discover advances in inhaled therapies• Discuss personalised therapy approaches, asthma

patient stratification and unmet needs• Share clinical practice ideas to improve the lives of

patients• Explore the latest thinking on biomarkers and

clinical trial endpoints• Update on mechanisms and treatment for viral

induced COPD and asthma exacerbations

SMi presents the 11th annual conference on…

Exploring the future of therapeutics,diagnosis and care

“Excellent meeting” Teva UKBO

OK BY

19TH

DEC

EMBE

R

AND SAVE £

400

BOOK B

Y 30T

H JANUARY

AND SAVE £

200

BOOK B

Y 27T

H FEBR

UARY

AND SAVE £

100

Register online at: www.asthma-copd.co.uk • Alternatively fax y

Asthma & COPD Day One | Monday 13th April 2015

8.30 Registration & Coffee

9.00 Chairman's Opening RemarksSebastian Johnston, Professor of Respiratory Medicine, NationalHeart and Lung Institute, Imperial College London

Asthma Pathways: Lab and Clinic

9.10 OPENING KEYNOTEChildren's asthma treatments are like children's clothes: makesure they fit•Severe asthma in children is pathophysiologically different to

the adult disease•Before reaching for the monoclonal, think: are the basics right?•When assessing results: did they CONSORT with the right

children•Planning trials: does the cap fit?Andrew Bush, Professor of Paediatric Respirology, ImperialCollege London and Royal Brompton Hospital

9.40 Unravelling mechanisms of asthma exacerbations andimplications for the future•Aetiology of asthma exacerbations•Deficient antiviral immunity in asthma•Epithelial immune interactions in asthma exacerbations•Implications for new therapiesSebastian Johnston, Professor of Respiratory Medicine, NationalHeart and Lung Institute, Imperial College London

10.10 Morning Coffee

10.40 Is neutrophilic/non-eosinophilic inflammation an appropriatetherapeutic target in asthma?•Which inflammatory phenotype to target: non-eosinophilic,

neutrophilic, Th2-low?•Trials and tribulations with licensed drugs including macrolides

for treating neutrophilic/non-eosinophilic asthma•Novel small molecules for treating neutrophilic/non-eosinophilic

asthma•Potential role for biological agents for treating

neutrophilic/non-eosinophilic asthmaNeil C Thomson, Professor of Respiratory Medicine, University ofGlasgow

11.10 Mechanisms mediating paediatric severe asthma: translationalapproaches•Pathology of paediatric severe asthma: inflammation and

remodelling•Steroid responsiveness in severe disease•Novel therapeutic targetsSejal Saglani, Reader in Respiratory Paediatrics, Imperial CollegeLondon

11.40 Cytokine regulation of pulmonary inflammation and remodellingin asthma•Can asthma phenotypes be modelled in vivo?•Is airway remodelling dependent on inflammation?•How do genes and environment affect development of

pathology?•Novel therapeutic avenuesClare Lloyd, Professor of Respiratory Immunology, ImperialCollege London

12.10 Networking Lunch

1.10 PARTNERSHIPS FOCUSChanging role of patient charities in research - what can we offer?•Benefits of working with charities to patients and wider society •What value can patient charities bring to multi-partner

collaborations? •The Asthma UK approach to establishing research partnerships

with industry •Examples of large collaborative research programmes that

Asthma UK is involved in and future ways of workingSamantha Walker, Executive Director, Research & Policy, Asthma UK

Personalised Therapeutics

1.40 Enabling targeted therapy for severe asthma through molecularphenotyping and biomarker development • Asthma heterogeneity impacts target, patient, and outcome

selection•A clinically valid biomarker comprises both the thing being

measured and the assay used to measure it•How to prove biomarker selection hypotheses in clinical studies•Beyond type 2 inflammation: new insights into asthma

phenotypesJoseph Arron, Associate Director, Biomarker Discovery, Genentech, Inc.

2.10 New therapeutic approaches for asthma: It's all about the airways• New biology is emphasizing the importance of the epithelium

and innate immune pathways as key orchestrators of asthma-associated pathology

• What clues have genetics provided regarding key pathwaysand risk factors?

• Asthma is not a single disease- the importance of stratificationand biomarkers

• Emerging targets and biomarker approaches from the new scienceDirk Smith, Scientific Director, Amgen

2.40 Eosinophilic inflammation and exacerbations of asthma andCOPD: A fatal liaison•Management of acute exacerbations in Asthma and COPD•The role of eosinophilic inflammation in Asthma and COPD•Development of monoclonal antibodies for the management

of severe Asthma and COPD•The need for personalized health careRoland Kolbeck, Senior Director, Respiratory, Inflammation &Autoimmunity, MedImmune

3.10 Afternoon Tea

3.40 Is the severe asthma phenotype stable?• Learnings from cluster analyses• Steroid-resistant phenotype in severe asthma• Challenges and opportunities in clinical researchHector Ortega, Medical Director, Respiratory R&D, GSK

4.10 The ADEPT study: airways disease endotyping for personalizedtherapeutics in asthma and COPD•It’s clear not all drugs work in all people; are you surprised?•Janssen wished to build up an internal database for asthma and

COPD to interrogate current and future therapeutic targets•We recruited 150 asthmatics and 30 healthy controls in PART 1

and 60 COPD and 60 healthy controls in Part 2. Most subjectshad bronchoscopies

•We have already gained great insights and the analysis hasonly just begun!

Philip E Silkoff, Senior Director, Immunology, Pulmonary DiseaseArea, Janssen Inc.

4.40 Chairman's Closing Remarks and Close of Day OneSebastian Johnston, Professor of Respiratory Medicine, NationalHeart and Lung Institute, Imperial College London

SPONSORSHIP AND EXHIBITION OPPORTUNITIES

SMi offer sponsorship, exhibition, advertising and brandingpackages, uniquely tailored to complement yourcompany’s marketing strategy.

Prime networking opportunities exist to entertain, enhanceand expand your client base within the context of anindependent discussion specific to your industry.

Should you wish to join the increasing number of companiesbenefiting from sponsoring our conferences please call:

Alia Malick on +44 (0) 20 7827 6168 or email: [email protected]

Official Media Partners

our registration to +44 (0)870 9090 712 or call +44 (0)870 9090 711

Asthma & COPD Day Two | Tuesday 14th April 2015

8.30 Registration & CoffeeRobert Niven, Senior Lecturer in Respiratory Medicine,Manchester University

9.00 Chairman's Opening RemarksSebastian Johnston, Professor of Respiratory Medicine, NationalHeart and Lung Institute, Imperial College London

9.10 ENABLING TECHNOLOGY FOCUSAlways on, always with you. The role of personal technology andthe digital economy in respiratory health• Why will we see increasingly widespread adoption of new

personal health technologies? • There’s an app for that: medical “apps” are likely to have a

significant role in respiratory health in the future• Google knows, do you? The trail left by your daily interactions

contains valuable health related data• Discuss examples of smart devices (including smart inhalers)

providing information that isn’t apparent to healthcareprofessionals

John Blakey, Senior Clinical Lecturer, Liverpool School of TropicalMedicine James Pinchin, Horizon DERC, University of Nottingham

Viruses in Asthma and COPD

9.50 Viruses in asthma and COPD• Contribution of viruses to exacerbations in asthma and COPD • Mechanisms of virus-induced exacerbations• Viral/bacterial co-infection• Future developmentsPatrick Mallia, Senior Clinical Lecturer, Imperial College London

10.20 Development of antivirals for the treatment/prevention of virusinduced exacerbations of asthma and COPD• Unmet clinical need• Target mechanisms: pathogen or host?• Therapies in development• Future therapeutic optionsPhillip Monk, Chief Scientific Officer, Synairgen

10.50 Morning Coffee

11.20 Drug development challenges associated with inhaled andintranasal antivirals• Device and dosing considerations• Indication and patient segmentation• Trial setting and endpointsStaffan Edsbacker, Global Project Director & Associate Professor,AstraZeneca R&D Mölndal & University of Lund

11.50 Round Table Discussion: Challenges and choices in stratified asthma therapeutics • How many interleukin targeting MABS will be enough?• What are the unmet needs in asthma and what is the

future for these groups?Robert Niven, Senior Lecturer in Respiratory Medicine,Manchester University

12.30 Networking Lunch

1.30 ENABLING TECHNOLOGY FOCUS Imaging lung structure and function with hyperpolarised gas MRI• Outline the role of functional lung imaging with multi-nuclear

MRI in obstructive airways disease• Emphasise the sensitivity of novel MRI methods to early lung

disease• Demonstrate the application of the methods in assessment of

novel respiratory therapeuticsJim Wild, Professor of Magnetic Resonance Physics, University ofSheffield

COPD: Present and Future

2.00 Ceramide 1-phosphate (C1P), a potential new therapeutic targetfor COPD• C1P reduces lung inflammation• C1P promotes cell growth, survival and migration• The mechanism whereby C1P exerts its anti-inflammatory

actions involve inhibition of sphingomyelinase and serinepalmitoyl transferase activities, reduction of pro-inflammatorycytokines, and inhibition of NF-kB

• C1P analogs are promising tools for developing new strategiesto treat COPD

Antonio Gomez-Munoz, Professor of Biochemistry and MolecularBiology, University of the Basque Country

2.30 RPL554 as a novel treatment for severe COPD• Unmet medical need in COPD• RPL554 as a treatment of COPD exacerbations• Additional potential indications for RPL554Jan-Anders Karlsson, CEO, Verona Pharma

3.00 Afternoon Tea

3.30 Pulmonary rehabilitation in the real world• Research vs Real Life • Drop out – is there an answer?• Mapping PR in London • Commissioning PRMaria Buxton, Consultant Respiratory Physiotherapist, LondonNorth West Healthcare NHS Trust

4.00 CLOSING ADDRESSCOPD: Unmet need and challenges in NHS Care• What are the key areas of unmet clinical need for COPD

clinical care?• What are the barriers to access for new drugs in current NHS

practice? • Who is prescribing new drugs in the NHS?• Which aspects of COPD urgently require new pharmaceutical

approaches?John Hurst, Consultant in Respiratory Medicine, University CollegeLondon

4.30 Chairman's Closing Remarks and Close of Day TwoRobert Niven, Senior Lecturer in Respiratory Medicine,Manchester University

Interested in promoting your services to this market?Contact Teri Arri, SMi Marketing on +44 (0) 207 827 6162 or email [email protected]

Supported by

HALF-DAY POST-CONFERENCE AM WORKSHOPWednesday 15th April 2015

8.30am - 12.30pmHoliday Inn Regents Park Hotel, London, UK

The power of functional respiratory imaging todefine new endpoints and drive successful

respiratory drug development

Workshop Leaders: Dr. Vos Wim, Chief Technology Officer, FLUIDDA,Prof. Dr. Wilfried De Backer, Director, Professor of

Pulmonary Medicine, University Hospital and Universityof Antwerp

Overview of workshop:This workshop focusses on overcoming the difficulties thatcompanies face when registering new respiratory drugs.It demonstrates that functional respiratory imaging is ableto provide new detailed insights and clear performancemeasures that can be vital for a successful outcome ofthe drug development process.

You should attend if you are interested in the potential ofsensitive innovative endpoints to provide decisionsmaking process in the early and clinical developmentphases of a device or drug to improve commercialoutcomes

Who should attend this workshop:• Decision makers in the development trajectory for

respiratory drugs• Individuals interested in alternative outcome

parameters in respiratory medicine

Programme:8.30 Registration and coffee

9.00 Opening remarks

9.15 The current development trajectory ofrespiratory drugs

10.15 Functional respiratory imaging (FRI)

10.45 Coffee break

11.15 The current status of FRI• Scientific evidence• Regulatory standpoint

11.45 Future perspectives of FRI• Drug development• Clinical practice

12.15 Closing remarks

12.30 End of workshop

About the host:Wim Vos is the CTO of FLUIDDA. Over the last 10 years hehas been responsible for the development of functionalimaging based outcome parameters in respiratory drugdevelopment. He is author of over 25 journal publicationsand over 100 conference abstracts.

Wilfried De Backer is the director of the department ofpulmonary medicine at the University Hospital and fullprofessor at the University of Antwerp. He also served asan expert for EMA and was head of the clinicalphysiology, sleep and pulmonary circulation assembly atERS. He is author of numerous books and publicationsand is considered an authority in his field.

About he ogranisation:FLUIDDA is the leading R&Dcompany in the field ofquantitative image analysis forrespiratory diseases. Its proprietaryFRI technology offers a unique entry point intopersonalized medicine by providing patient specificimaging biomarkers. Implementing FRI in early clinicalresearch results in a cost-effective and time-savingscreening of the most promising respiratory drugs.

SMI'S PHARMACEUTICAL PORTFOLIO 2015

SPONSORSHIP AND EXHIBITIONOPPORTUNITIES

SMi offer sponsorship, exhibition, advertising and branding packages, uniquely tailored to complement your company’s marketingstrategy.

Prime networking opportunities exist to entertain,enhance and expand your client base within thecontext of an independent discussion specific to your industry.

Should you wish to join the increasing number of companies benefiting fromsponsoring our conferences please call: Alia Malick on +44 (0) 20 7827 6168 or email: [email protected]

JANUARY

Pharmaceutical Microbiology21st – 22nd January 2015

Marriott Regents Park, London

Social Media in the Pharma Industry21st – 22nd January 2015


Pre Filled Syringes28th – 29th January 2015


FEBRUARY

Parallel Trade9th – 10th February 2015

Holiday Inn Regents Park, London

Advances and Progress in Drug Design16th – 17th February 2015


RNAi Therapeutics16th – 17th February 2015


MARCH

Superbugs & Superdrugs – A focus onAntibacterials

25th – 26th March 2015Holiday Inn Regents Park, London

Paediatric Clinical Trials25th – 26th March


APRIL

Asthma & COPD 13th – 14th April 2015


Adaptive Designs20th – 21st April 2015, London

Pre Filled Syringes USA27th – 28th April 2015, Iselin, USA

Lyophilisation and Freeze Drying USA29th – 30th April 2015, Iselin, USA

FAX your booking form to +44 (0) 870 9090 712PHONE on +44 (0) 870 9090 711

POST your booking form to: Events Team, SMi Group Ltd, 2nd FloorSouth, Harling House, 47-51 Great Suffolk Street, London, SE1 0BS, UK

ASTHMA & COPD Conference: Monday 13th & Tuesday 14th April 2015, Holiday Inn Regents Park Hotel, London, UK Workshop: Wednesday 15th April 2015, London

4 WAYS TO REGISTERwww.asthma-copd.co.uk

If you have any further queries please call the Events Team on tel +44 (0) 870 9090 711 or you can email [email protected]

Payment: If payment is not made at the time of booking, then an invoice will be issued and must bepaid immediately and prior to the start of the event. If payment has not been received then creditcard details will be requested and payment taken before entry to the event. Bookings within 7 daysof event require payment on booking. Access to the Document Portal will not be given until paymenthas been received.Substitutions/Name Changes: If you are unable to attend you may nominate, in writing, anotherdelegate to take your place at any time prior to the start of the event. Two or more delegates maynot ‘share’ a place at an event. Please make separate bookings for each delegate.Cancellation: If you wish to cancel your attendance at an event and you are unable to send asubstitute, then we will refund/credit 50% of the due fee less a £50 administration charge, providingthat cancellation is made in writing and received at least 28 days prior to the start of the event.Regretfully cancellation after this time cannot be accepted. We will however provide theconferences documentation via the Document Portal to any delegate who has paid but is unableto attend for any reason. Due to the interactive nature of the Briefings we are not normally able toprovide documentation in these circumstances. We cannot accept cancellations of orders placedfor Documentation or the Document Portal as these are reproduced specifically to order. If we haveto cancel the event for any reason, then we will make a full refund immediately, but disclaim anyfurther liability.Alterations: It may become necessary for us to make alterations to the content, speakers, timing,venue or date of the event compared to the advertised programme.Data Protection: The SMi Group gathers personal data in accordance with the UK Data ProtectionAct 1998 and we may use this to contact you by telephone, fax, post or email to tell you about otherproducts and services. Unless you tick here □ we may also share your data with third parties offeringcomplementary products or services. If you have any queries or want to update any of the data thatwe hold then please contact our Database Manager [email protected] or visitour website www.smi-online.co.uk/updates quoting the URN as detailed above your address on theattached letter.

Unique Reference Number

Our Reference LVP-135

Terms and Conditions of Booking

DELEGATE DETAILSPlease complete fully and clearly in capital letters. Please photocopy for additional delegates.

Title: Forename:

Surname:

Job Title:

Department/Division:

Company/Organisation:

Email:

Company VAT Number:

Address:

Town/City:

Post/Zip Code: Country:

Direct Tel: Direct Fax:

Mobile:

Switchboard:

Signature: Date:I agree to be bound by SMi's Terms and Conditions of Booking.

ACCOUNTS DEPT

Title: Forename:

Surname:

Email:

Address (if different from above):

Town/City:

Post/Zip Code: Country:

Direct Tel: Direct Fax:

VENUE Holiday Inn Regents Park Hotel, Carburton Street, London, W1W 5EE

□ Please contact me to book my hotelAlternatively call us on +44 (0) 870 9090 711, email: [email protected] or fax +44 (0) 870 9090 712

□ Book by 19th December 2014 to receive £400 off the conference price □ Book by 30th January 2015 to receive £200 off the conference price□ Book by 27th February 2015 to receive £100 off the conference price

EARLY BIRDDISCOUNT

Payment must be made to SMi Group Ltd, and received before the event, by one ofthe following methods quoting reference P-135 and the delegate’s name. Bookingsmade within 7 days of the event require payment on booking, methods of paymentare below. Please indicate method of payment:

□ UK BACS Sort Code 300009, Account 00936418□ Wire Transfer Lloyds TSB Bank plc, 39 Threadneedle Street, London, EC2R 8AU Swift (BIC): LOYDGB21013, Account 00936418 IBAN GB48 LOYD 3000 0900 9364 18□ Cheque We can only accept Sterling cheques drawn on a UK bank.□ Credit Card □ Visa □ MasterCard □ American Express All credit card payments will be subject to standard credit card charges.

Card No: □□□□ □□□□ □□□□ □□□□Valid From □□/□□ Expiry Date □□/□□CVV Number □□□□ 3 digit security on reverse of card, 4 digits for AMEX card

Cardholder’s Name:

Signature: Date:I agree to be bound by SMi's Terms and Conditions of Booking.

Card Billing Address (If different from above):

DOCUMENTATIONI cannot attend but would like to purchase access to the following DocumentPortal/paper copy documentation Price Total□ Access to the conference documentation

on the Document Portal £499.00 + VAT £598.80□ The Conference Presentations – paper copy £499.00 - £499.00

(or only £300 if ordered with the Document Portal)

PAYMENT

VATVAT at 20% is charged on the attendance fees for all delegates. VAT is also charged onDocument portal and literature distribution for all UK customers and for those EU Customersnot supplying a registration number for their own country here.______________________________________________________________________________________________

CONFERENCE PRICESI would like to attend: (Please tick as appropriate) Fee Total□ Conference and 1 Workshop £2098.00 +VAT £2517.60□ Conference only £1499.00 +VAT £1798.80□ 1 Workshop only £599.00 +VAT £718.80PROMOTIONAL LITERATURE DISTRIBUTION □ Distribution of your company’s promotional

literature to all conference attendees £999.00 + VAT £1198.80

The conference fee includes refreshments, lunch, conference papers, and access to theDocument Portal. Presentations that are available for download will be subject todistribution rights by speakers. Please note that some presentations may not be availablefor download. Access information for the document portal will be sent to the e-mailaddress provided during registration. Details are sent within 24 hours post conference.

Education

P 135 asthma and copd